Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising outcomes in initial patient assessments . Current inquiry https://thejillist.com/story11767546/retatrutide-emerging-investigations-and-projected-medical-uses